Is TGR5 the same as FXR?

No. Both are bile acid receptors and they are frequently confused. TGR5 is a cell-surface G-protein-coupled receptor; FXR is a nuclear receptor that regulates gene transcription, including of genes controlling bile acid synthesis. They respond to overlapping ligands and do entirely different things.

Why do L cells get denser further down the gut?

The distribution reflects what each region does. Distal segments encounter nutrients only when substantial quantities have escaped proximal absorption, which is a meaningful signal about meal size, and the hormonal responses that follow are correspondingly stronger.

Does this mean eating more fat raises GLP-1?

Fat intake triggers bile release, and bile acids sensitise L cells to nutrient stimuli - so the pathway exists. Whether that produces a change in circulating GLP-1 large enough to matter is a quantitative question the mechanism does not answer.

Are bile acid supplements relevant here?

Nothing in this article concerns any supplement or product, and no such recommendation is made or implied. It describes a receptor and what activating it does in cell and animal experiments.

GLP-1 & Incretin Science

Why Where Bile Arrives Changes How Much GLP-1 Comes Out

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-242 cited sources

Bile acids activate GPBAR1, also called TGR5, on intestinal L cells, raising cyclic AMP and amplifying the cell's response to glucose. Delivering bile to more distal regions of the ileum augments L-cell stimulation, which is the mechanistic link to surgical rerouting.

Key facts

Receptor: GPBAR1, also written TGR5 or GPBA
Immediate signal: Rapid elevation of cyclic AMP
Direct calcium response: Small
Interaction with glucose: Synergy reported
Effect on poorly glucose-responsive cells: Became robustly glucose-responsive
In vivo finding: Distal bile delivery augmented L-cell stimulation
Cell model used: GLUTag cells and primary intestinal cultures
Source: Parker HE et al., Br J Pharmacol 2012 (PMID 21718300)

Bile acids do a second job

Bile acids are usually introduced as detergents: molecules that emulsify dietary fat so that lipases can act on it. That is true and incomplete. They are also ligands, recognised by specific receptors that treat their arrival as information rather than as chemistry. One of those receptors, GPBAR1 - more often written TGR5 - sits on intestinal L cells, the cells that release GLP-1. From the cell's point of view, the arrival of bile is a reliable signal that a meal containing fat has been eaten and is being processed.

What activating the receptor does

Parker and colleagues found that bile acids and a synthetic agonist increased GLP-1 secretion from intestinal cultures, and characterised the signalling. Activation produced rapid elevation of cyclic AMP in individual GLUTag cells. Direct calcium responses to the agonist were small - so this is not primarily a receptor that triggers secretion on its own. What it does instead is more interesting: in the presence of the agonist, a subpopulation of cells that had previously been poorly glucose-responsive exhibited robust glucose responses. The receptor is a sensitiser. It changes how strongly the cell reacts to a different stimulus.

Why sensitisation is a more useful mechanism than direct triggering

A signal that simply causes secretion produces GLP-1 whenever it is present, including at times when no nutrients have arrived. A signal that raises the gain on nutrient detection produces GLP-1 only when nutrients are also present, and produces more of it than nutrients alone would. The authors report evidence for synergy between the effects of glucose and receptor activation, which is what that arrangement looks like in data. It also means the same glucose stimulus can produce very different amounts of GLP-1 depending on what else has reached that stretch of intestine.

The finding that explains the surgical result

In vivo, increased delivery of bile to more distal regions of the ileum augmented L-cell stimulation. L cells are not distributed evenly along the gut - their density increases toward the distal small intestine and colon - so where a stimulus arrives determines how many of them encounter it. Ordinarily bile is released into the duodenum and largely reabsorbed before reaching the ileum, so the L-cell-dense regions see comparatively little. Any arrangement that delivers bile further down puts a sensitising signal where the cells are, and the response rises. That is the mechanistic core of why rerouting operations are associated with large increases in postprandial GLP-1, and it is a structural explanation rather than a metabolic one.

What has not followed from it

A drug. TGR5 agonism has been pursued on exactly the reasoning above and has not produced a licensed weight-management medicine, which is the same fate as the other secretion-stimulating strategies. The receptor is expressed in tissues beyond the L cell, including gallbladder, which constrains systemic agonism; and the ceiling on what any secretagogue can achieve is set by how much GLP-1 the cells can release and how quickly DPP-4 removes it. Raising the gain on a system with a low ceiling is a different proposition from bypassing the ceiling altogether, which is what a receptor agonist does.

Reading claims about this pathway

Statements linking bile, fat intake or gut anatomy to GLP-1 are engaging a real and well-characterised mechanism. The mechanism being real says nothing about the size of the effect, its duration, or whether it resembles what a pharmacological agonist produces. Nothing described here is a product or a treatment, and nothing supplied on this site engages any receptor discussed in this article.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is TGR5 the same as FXR?: No. Both are bile acid receptors and they are frequently confused. TGR5 is a cell-surface G-protein-coupled receptor; FXR is a nuclear receptor that regulates gene transcription, including of genes controlling bile acid synthesis. They respond to overlapping ligands and do entirely different things.
Why do L cells get denser further down the gut?: The distribution reflects what each region does. Distal segments encounter nutrients only when substantial quantities have escaped proximal absorption, which is a meaningful signal about meal size, and the hormonal responses that follow are correspondingly stronger.
Does this mean eating more fat raises GLP-1?: Fat intake triggers bile release, and bile acids sensitise L cells to nutrient stimuli - so the pathway exists. Whether that produces a change in circulating GLP-1 large enough to matter is a quantitative question the mechanism does not answer.
Are bile acid supplements relevant here?: Nothing in this article concerns any supplement or product, and no such recommendation is made or implied. It describes a receptor and what activating it does in cell and animal experiments.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum